Glycaemic control with add-on thiazolidinedione or a sodium-glucose co-transporter-2 inhibitor in patients with type 2 diabetes after the failure of an oral triple antidiabetic regimen: A 24-week, randomized controlled trial

被引:7
作者
Bae, Jaehyun [1 ]
Huh, Ji Hye [2 ,3 ]
Lee, Minyoung [4 ]
Lee, Yong-Ho [4 ]
Lee, Byung-Wan [4 ]
机构
[1] Catholic Kwandong Univ, Int St Marys Hosp, Coll Med, Div Endocrinol & Metab,Dept Internal Med, Incheon, South Korea
[2] Hallym Univ, Sacred Heart Hosp, Dept Internal Med, Div Endocrinol & Metab, Anyang, South Korea
[3] Yonsei Univ, Wonju Coll Med, Dept Internal Med, Div Endocrinol & Metab, Wonju, South Korea
[4] Yonsei Univ, Coll Med, Dept Internal Med, Div Endocrinol & Metab, 50 Yonsei Ro, Seoul 120752, South Korea
关键词
quadruple combination antidiabetic agents; SGLT2; inhibitor; thiazolidinedione; type; 2; diabetes; MANAGEMENT; MELLITUS; THERAPY;
D O I
10.1111/dom.14259
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aim To evaluate the effectiveness and safety of adding either a sodium-glucose co-transporter-2 inhibitor (SGLT2i) or thiazolidinedione (TZD) in patients with type 2 diabetes (T2D) inadequately controlled with triple therapy. Materials and Methods In this prospective, open-label, multicentre, 24-week clinical trial, we randomly assigned 119 patients with T2D who failed to achieve glycaemic control (7% < HbA1c <= 10%) with conventional triple oral antidiabetic agents (OADs; metformin, sulphonylurea and dipeptidyl peptide-4 [DPP-4] inhibitor) into two groups who received either an SGLT2i or TZD. The primary endpoint was mean change in HbA1c level between the two groups at 24 weeks. Results In total, 119 patients were enrolled in the SGLT2i (n = 60) and TZD (n = 59) groups. Mean age of the study subjects was 61.86 years, and the mean duration of T2D was 13.89 years. After 24 weeks, both groups showed significant reductions in HbA1c (from 7.94% +/- 0.74% to 6.97% +/- 0.84% in the SGLT2i group and from 8.00% +/- 0.78% to 7.18% +/- 0.98% in the TZD group), without a significant between-group difference (P = .235). A significant body mass index (BMI) reduction was noted in the SGLT2i group, whereas an increase in BMI was noted in the TZD group (-0.79 +/- 1.37 vs. 0.92 +/- 0.86 kg/m(2), P < .001). Other safety profiles were favourable in both groups. Conclusions The current study shows that an SGLT2i or TZD could be a valid option as a fourth OAD for treatment of patients with T2D inadequately controlled with a triple combination of OADs.
引用
收藏
页码:609 / 618
页数:10
相关论文
共 25 条
[2]   Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus A Randomized Trial [J].
Cusi, Kenneth ;
Orsak, Beverly ;
Bril, Fernando ;
Lomonaco, Romina ;
Hecht, Joan ;
Ortiz-Lopez, Carolina ;
Tio, Fermin ;
Hardies, Jean ;
Darland, Celia ;
Musi, Nicolas ;
Webb, Amy ;
Portillo-Sanchez, Paola .
ANNALS OF INTERNAL MEDICINE, 2016, 165 (05) :305-+
[3]   Pathogenesis of type 2 diabetes mellitus [J].
DeFronzo, RA .
MEDICAL CLINICS OF NORTH AMERICA, 2004, 88 (04) :787-+
[4]   From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus [J].
DeFronzo, Ralph A. .
DIABETES, 2009, 58 (04) :773-795
[5]   Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events):: a randomised controlled trial [J].
Dormandy, JA ;
Charbonnel, B ;
Eckland, DJA ;
Erdmann, E ;
Massi-Benedetti, M ;
Kmoules, IK ;
Skene, AM ;
Tan, MH ;
Lefébvre, PJ ;
Murray, GD ;
Standl, E ;
Wilcox, RG ;
Wlhelmsen, L ;
Betteridge, J ;
Birkeland, K ;
Golay, A ;
Heine, RJ ;
Korányi, L ;
Laakso, M ;
Mokán, M ;
Norkus, A ;
Pirags, V ;
Podar, T ;
Scheen, A ;
Scherbaum, W ;
Schernthaner, G ;
Schmitz, O ;
Skrha, J ;
Smith, U ;
Taton, J .
LANCET, 2005, 366 (9493) :1279-1289
[6]  
Garber AJ, 2020, ENDOCR PRACT, V26, P107, DOI 10.4158/CS-2019-0472
[7]   Effectiveness and Safety of Adding Basal Insulin Glargine in Patients with Type 2 Diabetes Mellitus Exhibiting Inadequate Response to Metformin and DPP-4 Inhibitors with or without Sulfonylurea [J].
Kang, Yu Mi ;
Jung, Chang Hee ;
Lee, Seung-Hwan ;
Kim, Sang-Wook ;
Song, Kee-Ho ;
Kim, Sin Gon ;
Kim, Jae Hyeon ;
Cho, Young Min ;
Park, Tae Sun ;
Ku, Bon Jeong ;
Koh, Gwanpyo ;
Kim, Dol Mi ;
Lee, Byung-Wan ;
Park, Joong-Yeol .
DIABETES & METABOLISM JOURNAL, 2019, 43 (04) :432-446
[8]   Barriers to Insulin Initiation The Translating Research Into Action for Diabetes Insulin Starts Project [J].
Karter, Andrew J. ;
Subramanian, Usha ;
Saha, Candan ;
Crosson, Jesse C. ;
Parker, Melissa M. ;
Swain, Bix E. ;
Moffet, Howard H. ;
Marrero, David G. .
DIABETES CARE, 2010, 33 (04) :733-735
[9]   Diabetes Fact Sheets in Korea, 2018: An Appraisal of Current Status [J].
Kim, Bo-Yeon ;
Won, Jong Chul ;
Lee, Jae Hyuk ;
Kim, Hun-Sung ;
Park, Jung Hwan ;
Ha, Kyoung Hwa ;
Won, Kyu Chang ;
Kim, Dae Jung ;
Park, Kyong Soo .
DIABETES & METABOLISM JOURNAL, 2019, 43 (04) :487-494
[10]   Efficacy and Safety of Pioglitazone versus Glimepiride after Metformin and Alogliptin Combination Therapy: A Randomized, Open-Label, Multicenter, Parallel-Controlled Study [J].
Kim, Jeong Mi ;
Kim, Sang Soo ;
Kim, Jong Ho ;
Kim, Mi Kyung ;
Kim, Tae Nyun ;
Lee, Soon Hee ;
Lee, Chang Won ;
Park, Ja Young ;
Kim, Eun Sook ;
Lee, Kwang Jae ;
Choi, Young Sik ;
Kim, Duk Kyu ;
Kim, In Joo .
DIABETES & METABOLISM JOURNAL, 2020, 44 (01) :67-77